

NORTH AMERICAN

PEDIATRIC ALLERGY & ASTHMA CONGRESS | SEPT 21-22 '22



THE AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY

THE CANADIAN SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY



Conflict of Interest Declarations

Speakers & Moderators

Date	Session Title	Speakers	COI	Co-development Partner
Sept 21	OIT: What have we learned?	Dr. Paul Turner, Dr. Philippe Bégin(moderator)	<p>Dr. Paul Turner:Employment, personal fees/honoraria-Imperial College London, UK Health Security Agency (EMPLOYMENT); UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, Novartis (Honoraria).Advisory Board-UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, Novartis.Research grants (via university)-Medical Research Council, EU Commission, NIHR, JM Charity Foundation, Action Medical Research.I intend to use trade names during my presentation-Palforzia.</p> <p>I am currently participating in or have participated in clinical trials pertinent to the Guidelines.-Novartis, Aimmune, Investigator-led studies. Dr. Bégin:Ad boards and speaker engagements-Novartis, Sanofi-Genzyme, Aralez, ALK, Astra-Zeneca, Bausch Health, DBV Technologies, Pfizer.Investigator on clinical trials-Novartis, Sanofi, Regeneron, DBV technologies.I intend to make therapeutic recommendations for medications that have not received regulatory approval. Participation to advisory boards-Novartis, Aralez, ALK, DBV Technologies, Sanofi-Genzyme, Bausch Health, Pfizer, Astra-Zeneva. Speaking engagements-Novartis, ALK, Sanofi-Genzyme, Bausch Health.I have received a grant(s) or an honorarium from a commercial organization.-DBV technologies, Novartis, Regeneron, Sanofi.</p>	
Sept 21	Preparing families for their OIT journey	Dr.Douglas Mack, Dr. Philippe Bégin(moderator)	<p>Dr. Douglas Mack:Advisory Board Chair, Member and speaker-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Funded grants or clinical trials-ALK, Arcutis, Dermavant, DBV. I intend to make therapeutic recommendations for medications that have not received regulatory approval. Advisory Board Chair or Member-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS.Speaker-Bausch Health, Miravo, Medexus, Pfizer, ALK, COVIS.Investigator-ALK, Dermavant, Arcutis, DBVDr. Bégin:Ad boards and speaker engagements-Novartis, Sanofi-Genzyme, Aralez, ALK, Astra-Zeneca, Bausch Health, DBV Technologies, Pfizer.Investigator on clinical trials-Novartis, Sanofi, Regeneron, DBV technologies.I</p>	

intend to make therapeutic recommendations for medications that have not received regulatory approval. Participation to advisory boards-Novartis, Aralez, ALK, DBV Technologies, Sanofi-Genzyme, Bausch Health, Pfizer, Astra-Zeneva. Speaking engagements-Novartis, ALK, Sanofi-Genzyme, Bausch Health.I have received a grant(s) or an honorarium from a commercial organization.-DBV technologies, Novartis, Regeneron, Sanofi.

Sept 21	Pro/Con: OIT is the new standard of care	Dr. Arnon Elizur vs Dr. David Stukus, Dr. Philippe Bégin(moderator)	<p>Dr. Arnon Elizur: Advisory Board-Sanofi. Dr. David Stukus:Consultant for all companies; Honoraria for ACAAI and AAP-Before Brands, DBV Technologies, ARS Pharmaceuticals, Novartis, American College of Allergy Asthma and Immunology, American Academy of Pediatrics</p> <p>Dr. Bégin:Ad boards and speaker engagements-Novartis, Sanofi-Genzyme, Aralez, ALK, Astra-Zeneca, Bausch Health, DBV Technologies, Pfizer.Investigator on clinical trials-Novartis, Sanofi, Regeneron, DBV technologies.I intend to make therapeutic recommendations for medications that have not received regulatory approval. Participation to advisory boards-Novartis, Aralez, ALK, DBV Technologies, Sanofi-Genzyme, Bausch Health, Pfizer, Astra-Zeneva. Speaking engagements-Novartis, ALK, Sanofi-Genzyme, Bausch Health.I have received a grant(s) or an honorarium from a commercial organization.-DBV technologies, Novartis, Regeneron, Sanofi.</p>
Sept 21	Advanced OIT Breakouts	Dr. Douglas Mack (moderator)	<p>Dr. Douglas Mack:Advisory Board Chair, Member and speaker-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Funded grants or clinical trials-ALK, Arcutis, Dermavant, DBV. I intend to make therapeutic recommendations for medications that have not received regulatory approval. Advisory Board Chair or Member-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS.Speaker-Bausch Health, Miravo, Medexus, Pfizer, ALK, COVIS.Investigator-ALK, Dermavant, Arcutis, DBV</p>

Sept 21	Practical OIT breakouts	Dr. David Stukus (moderator)	Dr. David Stukus: Consultant for all companies; Honoraria for ACAAI and AAP-Before Brands, DBV Technologies, ARS Pharmaceuticals, Novartis, American College of Allergy Asthma and Immunology, American Academy of Pediatrics	
Sept 21	Fireside Chat	Dr. David Stukus moderator), Speakers-Dr. Aikaterini Anagnostou, Dr. Arnon Elizur, Dr. Paul Turner, Dr. Edwin Kim, Dr. Douglas Mack	<p>Dr. Douglas Mack:Advisory Board Chair, Member and speaker-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Funded grants or clinical trials-ALK, Arcutis, Dermavant, DBV. I intend to make therapeutic recommendations for medications that have not received regulatory approval. Advisory Board Chair or Member-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Speaker-Bausch Health, Miravo, Medexus, Pfizer, ALK, COVIS. Investigator-ALK, Dermavant, Arcutis, DBV. Dr. David Stukus:Consultant for all companies; Honoraria for ACAAI and AAP-Before Brands, DBV Technologies, ARS Pharmaceuticals, Novartis, American College of Allergy Asthma and Immunology, American Academy of Pediatrics.</p> <p>Dr. Arnon Elizur: Advisory Board-Sanofi. Dr. Paul Turner:Employment, personal fees/honoraria-Imperial College London, UK Health Security Agency (EMPLOYMENT); UK Food Standards Agency, Aimmune Therapeutics, Allergenics, Aquestive Therapeutics, Novartis (Honoraria). Advisory Board-UK Food Standards Agency, Aimmune Therapeutics, Allergenics, Aquestive Therapeutics, Novartis. Research grants (via university)-Medical Research Council, EU Commission, NIHR, JM Charity Foundation, Action Medical Research I intend to use trade names during my presentation-Palforzia. I am currently participating in or have participated in clinical trials pertinent to the Guidelines.-Novartis, Aimmune, Investigator-led studies. Dr. Aikaterini Anagnostou:WEBINAR SPONSORED SPEAKER-AIMMUNE THERAPEUTICS. ADVISORY BOARD-DBV TECHNOLOGIES. Funded grants or clinical trials-AIMMUNE THERAPEUTICS, NOVARTIS. CONSULTANT-ALK. I have received a grant(s) or an honorarium from a commercial organization-AIMMUNE, NOVARTIS. I am currently participating in or have participated in clinical trials pertinent to the Guidelines-AIMMUNE, NOVARTIS. Dr. Edwin Kim:Consulting-AllerGenis, Allergy Therapeutics Ltd, Belhaven Pharma, Duke Clinical Research Institute, Genentech, Nutricia. Advisory Board-ALK, Kenota Health, Ukko Inc. Grant to university-NIH/NIAID, FARE. advisory boards and consulting-ALK, Kenota Health, Ukko Inc, AllerGenis, Allergy Therapeutics Ltd, Belhaven Pharma, Duke Clinical Research Institute,</p>	Miravo

Genentech, Nutricia. Grant to my university-
FAREPI of clinical trials-Aimmune, DBV
Technologies, Regeneron, HAL Allergy, Astellas
Pharma, Genentech, Novartis, AllAdapt,
AnaptysBio

Sept 22	SLIT Breakfast	Moderator: Dr. Mariam A. Hanna, Speaker-Dr. Edwin Kim	<p>Dr. Edwin Kim:Consulting-AllerGenis, Allergy Therapeutics Ltd, Belhaven Pharma, Duke Clinical Research Institute, Genentech, Nutricia. Advisory Board-ALK, Kenota Health, Ukko Inc. Grant to university-NIH/NIAID, FARE. advisory boards and consulting-ALK, Kenota Health, Ukko Inc, AllerGenis, Allergy Therapeutics Ltd, Belhaven Pharma, Duke Clinical Research Institute, Genentech, Nutricia. Grant to my university-FAREPI of clinical trials-Aimmune, DBV Technologies, Regeneron, HAL Allergy, Astellas Pharma, Genentech, Novartis, AllAdapt, AnaptysBio.</p> <p>Dr. Mariam A. Hanna:Honoraria for speaking events, product development-Pfizer, ALK, COVIS, Pediapharm, Miravo. Participated in advisory board-ALK, Bausch, Merck. Clinical trials for eczema, food allergy, and dust mite allergy-Arcutis, Dermavant, DBV, ALK. I intend to make therapeutic recommendations for medications that have not received regulatory approval. I have received direct payment from patients or their parents/guardians for my clinical activities.</p>	ALK
Sept 22	Food Allergy Prevention: What are we missing?	Moderator: Dr. Elana Lavine, Speaker- Dr. Elissa Abrams	<p>Dr. Elana Lavine: receipt of honouraria for attending virtual advisory board meetings-Medexus Pharmaceuticals, ALK, Miravo. Current pediatric section advisor-CSACI.</p> <p>Dr. Elissa Abrams:Employee-Public Health Agency of Canada.</p>	
Sept 22	The Latest Perspective on FPIES and non-IgE Mediated Food Allergy	Speaker- Dr. Anna Nowak-Wegryzn	<p>Dr. Anna Nowak-Wegryzn: honoraria for lectures, associate editor for the Annals of Allergy, Asthma and Immunology-Thermofisher, Nestle, Danone Nutricia, Aimmune, Hanimmune,ACAAI. Advisory Board-Novartis. clinical trials, grant to study immunology of FPIES-Alladapt, DBV, Regeneron, NIAID. I intend to make therapeutic recommendations for medications that have not received regulatory approval.food allergy, baked milk/egg, epi sublingual-Novartis, Hanimmune, Aquestive. clinical trials-Alladapt, DBV, Regeneron.</p>	
Sept 22	Pro/Con: Asthma is a risk factor for food allergy outcomes	Speaker-Dr. Aikaterini Anagnostou vs Dr. Paul Turner	<p>Dr. Paul Turner:Employment, personal fees/honoraria-Imperial College London, UK Health Security Agency (EMPLOYMENT); UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, Novartis (Honoraria).Advisory Board-UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, Novartis.Research grants (via university)-Medical Research</p>	

Council, EU Commission, NIHR, JM Charity Foundation, Action Medical Research I intend to use trade names during my presentation-Palforzia.

I am currently participating in or have participated in clinical trials pertinent to the Guidelines.-Novartis, Aimmune, Investigator-led studies.

Dr.

Aikaterini Anagnostou:WEBINAR SPONSORED SPEAKER-AIMMUNE THERAPEUTICS.ADVISORY BOARD-DBV TECHNOLOGIES. Funded grants or clinical trials-AIMMUNE THERAPEUTICS, NOVARTIS.CONSULTANT-ALK. I have received a grant(s) or an honorarium from a commercial organization-AIMMUNE, NOVARTIS.

I am currently participating in or have participated in clinical trials pertinent to the Guidelines-AIMMUNE, NOVARTIS.

Sept 22

The most important articles you haven't read this year...and what's wrong with them

Moderator: Dr. Anna Nowak-Wegryzn, Speakers-Dr. Moshe Ben Shoshan, Dr. Aikaterini Anagnostou, Dr. Elissa Abrams

Dr. Aikaterini Anagnostou:WEBINAR SPONSORED SPEAKER-AIMMUNE THERAPEUTICS.ADVISORY BOARD-DBV TECHNOLOGIES. Funded grants or clinical trials-AIMMUNE THERAPEUTICS, NOVARTIS.CONSULTANT-ALK. I have received a grant(s) or an honorarium from a commercial organization-AIMMUNE, NOVARTIS.

I am currently participating in or have participated in clinical trials pertinent to the Guidelines-AIMMUNE, NOVARTIS.

Dr. Elissa Abrams:Employee-Public Health Agency of Canada.

Dr. Anna Nowak-Wegryzn: honoraria for lectures, associate editor for the Annals of Allergy, Asthma and Immunology-Thermofisher, Nestle, Danone Nutricia, Aimmune, Hanimmune,ACAAI. Advisory Board-Novartis. clinical trials, grant to study immunology of FPIES-Alladapt, DBV, Regeneron, NIAID. I intend to make therapeutic recommendations for medications that have not received regulatory approval.food allergy, baked milk/egg, epi sublingual-Novartis, Hanimmune, Aquestive. clinical trials-Alladapt, DBV, Regeneron.

Dr. Moshe Ben-Shoshan: speaker , consultant-Novartis consultant Sanofi Consultant. advisor-Novartis, Sanofi. PI for Montreal site CQGE031C2302E1 study-Novartis - ligelizumab in CU. speaker-Miravo , Bausch. Note: Only generic names should be used whenever possible. Consultant for

Sept 22	Choose Your Own Adventure: The future of this infant with atopic dermatitis is in your hands	Moderator: Dr. Anna Nowak-Wegryzn, Speaker-Dr. Matthew Greenhawt	<p>Novartis Medexus , Sanofi , Bauch, Miravo and Stallergenes Greer. Consultant for Novartis Medexus , Sanofi , Bauch, Miravo and Stallergenes Greer (less than 3000CAD). I am currently participating in or have participated in clinical trials pertinent to the Guidelines.-Igelizumab and chronic urticaria.</p> <p>Dr. Matthew Greenhawt: honoraria for advisory boards or talks-DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, ProtA, ImSci, MedLearningGroup, RMEI Medical Education and multiple state/local allergy societies..medical advisory boards-DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, and ProtA.Engaged in a multi center clinical trial for leglizumab, paid to university not to me-Novartis. editor of a journal- Senior associate editor, Annals of Allergy, Asthma, Immunology. I intend to use trade names during my presentation. I intend to make therapeutic recommendations for medications that have not received regulatory approval. advisory boards-for DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, and ProtA. multi center clinical trials with all payment to university not me-Novartis, DBV.</p>
Sept 22	Epinephrine - Current use and future strategies	Moderator: Dr. David Stukus, Speaker-Dr. Jay Lieberman	<p>Dr. David Stukus:Consultant for all companies; Honoraria for ACAAI and AAP-Before Brands, DBV Technologies, ARS Pharmaceuticals, Novartis, American College of Allergy Asthma and Immunology, American Academy of Pediatrics.</p> <p>Dr. Jay Lieberman: Advisory Board Member-Novartis, ALK, Aquestive, Genentech, Novartis. Local site PI for clinical trials, money to institution-Aimmune, DBV, Regeneron, Novartis .Advisory Board member-Novartis, ALK, Aquestive, Genentech, Novartis.Local site PI for clinical trials, money to institution-Aimmune, DBV, Regeneron, Novartis.</p>
Sept 22	Biologics: Current and Future Applications for Food Allergy Treatment	Moderator: Dr. Moshe Ben-Shoshan, Speaker-Dr. Sharon Chinthrajah	<p>Dr. Sharon Chinthrajah: Advisory board member-Alladapt Therapeutics, Intrommune Therapeutics, Allergenis, Novartis, and Genentech. Grant support-National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research (CoFAR), Regeneron, DBV Technologies, Aimmune Therapeutics, Novartis, and</p>

			Sanofi. Grant support-Aimmune Therapeutics, Novartis, and Sanofi. Dr. Moshe Ben-Shoshan: speaker , consultant-Novartis consultant Sanofi Consultant. advisor-Novartis, Sanofi. PI for Montreal site CQGE031C2302E1 study-Novartis - ligelizumab in CU. speaker-Miravo , Bausch. Note: Only generic names should be used whenever possible. Consultant for Novartis Medexus , Sanofi , Bauch, Miravo and Stallergenes Greer. Consultant for Novartis Medexus , Sanofi , Bauch, Miravo and Stallergenes Greer (less than 3000CAD). I am currently participating in or have participated in clinical trials pertinent to the Guidelines.-ligelizumab and chronic urticaria.
Sept 22	The role of antihistamines and other adjunctive medications in the food allergy treatment plan	Moderator: Dr. Moshe Ben-Shoshan, Speaker-Dr. Antonella Muraro	Dr. Antonella Muraro: Member of Executive Committee and ANACare Steering Committee-Global Allergy and Asthma Network of Centres of Excellence -GA2LEN ANACARE. Advisory Board and speaker's bureau-Aimmune , DVB Technologies , Novartis, Sanofi Regeneron , Viatris. Principal investigator-Aimmune , DVB Technologies , Novartis , Sanofi Regeneron. I intend to make therapeutic recommendations for medications that have not received regulatory approval. Speaker's fee-Aimmune , DVB Technologies , Viatris.
Sept 22	Food ladders should be offered to all milk and egg allergic children	Moderator: Dr. Moshe Ben-Shoshan, Speaker-Dr. Matthew Greenhawt	
Sept 22	Anaphylaxis, Anxiety & Angst	Moderator: Dr. Douglas Mack, Speaker- Dr. Elana Lavine	Dr. Douglas Mack:Advisory Board Chair, Member and speaker-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Funded grants or clinical trials-ALK, Arcutis, Dermavant, DBV. I intend to make therapeutic recommendations for medications that have not received regulatory approval. Advisory Board Chair or Member-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS.Speaker-Bausch Health, Miravo, Medexus, Pfizer, ALK, COVIS.Investigator-ALK, Dermavant, Arcutis, DBV. Dr. Elana Lavine: receipt of honouraria for attending virtual advisory board meetings-Medexus Pharmaceuticals, ALK, Miravo. Current pediatric section advisor-CSACI.

Sept 22

Fireside Chat

Moderator: Dr. Douglas Mack, Speakers-Dr. Matthew Greenhawt, Dr. Elissa Abrams, Dr. Jay Lieberman, Dr. David Stukus

Dr. Douglas Mack: Advisory Board Chair, Member and speaker-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Funded grants or clinical trials-ALK, Arcutis, Dermavant, DBV.

I intend to make therapeutic recommendations for medications that have not received regulatory approval. Advisory Board Chair or Member-Bausch Health, Miravo, Medexus, Aimmune, Pfizer, ALK, COVIS. Speaker-Bausch Health, Miravo, Medexus, Pfizer, ALK, COVIS. Investigator-ALK, Dermavant, Arcutis, DBV.

Dr. David Stukus: Consultant for all companies; Honoraria for ACAAI and AAP-Before Brands, DBV Technologies, ARS Pharmaceuticals, Novartis, American College of Allergy Asthma and Immunology, American Academy of Pediatrics.

Dr. Elissa Abrams: Employee-Public Health Agency of Canada. Dr. Matthew Greenhawt: honoraria for advisory boards or talks-DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, ProtA, ImSci, MedLearningGroup, RMEI Medical Education and multiple state/local allergy societies..medical advisory boards-DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, and ProtA. Engaged in a multi center clinical trial for leglizumab, paid to university not to me-Novartis. editor of a journal- Senior associate editor, Annals of Allergy, Asthma, Immunology. I intend to use trade names during my presentation. I intend to make therapeutic recommendations for medications that have not received regulatory approval. advisory boards-for DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, and ProtA. multi center clinical trials with all payment to university not me-Novartis, DBV.

Dr. Jay Lieberman: Advisory Board Member-Novartis, ALK, Aquestive, Genentech, Novartis. Local site PI for clinical trials, money to institution-Aimmune, DBV, Regeneron, Novartis .Advisory Board member-Novartis, ALK, Aquestive, Genentech, Novartis. Local site PI for clinical trials, money to institution-Aimmune, DBV, Regeneron, Novartis.

Medexus